Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Bellemain-Appaix

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Journal of the American College of Cardiology|January 3, 2024
Clopidogrel for Long-Term Secondary Prevention After Coronary Artery StentingAnne Bellemain-Appaix, Gilles Montalescot
International Journal of Cardiology|April 4, 2015
Impressive progression of coronary artery disease assessed by serial multimodality imaging in a 40 year-old patient with Behçet's diseaseSofiene Rekik, François Bernasconi, Armand Eker, et al.
Circulation|November 19, 2014
Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategyJean-Philippe Collet, Johanne Silvain, Anne Bellemain-Appaix, et al.
Circulation. Cardiovascular Interventions|February 18, 2011
Optimal use of thienopyridines in non-ST-elevation acute coronary syndrome following CURRENT-OASIS 7Johanne Silvain, Anne Bellemain-Appaix, Olivier Barthélémy, et al.
The American Journal of Cardiology|August 21, 2010
Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event ratesFarzin Beygui, Johanne Silvain, Ana Pena, et al.
Journal of the American College of Cardiology|August 31, 2010
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysisAnne Bellemain-Appaix, David Brieger, Farzin Beygui, et al.
Circulation. Cardiovascular Interventions|October 6, 2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patientsJean-Sébastien Hulot, Jean-Philippe Collet, Guillaume Cayla, et al.
Journal of the American College of Cardiology|July 13, 2010
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysisJean-Sébastien Hulot, Jean-Philippe Collet, Johanne Silvain, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 8, 2024
Impact of coronary sinus reducer on absolute coronary blood flow and microvascular resistanceClément Servoz, Stefan Verheye, Francesco Giannini, et al.
Case Reports in Cardiology|September 13, 2021
Anomalous Left Coronary Artery Connected to the Pulmonary Artery in a 15-Year-Old Girl: Case Report and Discussion on Secondary Prevention of Sudden DeathJérémy Laïk, Virginie Fouilloux, Philippe Aldebert, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Journal of the American College of Cardiology|January 3, 2024
Clopidogrel for Long-Term Secondary Prevention After Coronary Artery StentingAnne Bellemain-Appaix, Gilles Montalescot
International Journal of Cardiology|April 4, 2015
Impressive progression of coronary artery disease assessed by serial multimodality imaging in a 40 year-old patient with Behçet's diseaseSofiene Rekik, François Bernasconi, Armand Eker, et al.
Circulation|November 19, 2014
Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategyJean-Philippe Collet, Johanne Silvain, Anne Bellemain-Appaix, et al.
Circulation. Cardiovascular Interventions|February 18, 2011
Optimal use of thienopyridines in non-ST-elevation acute coronary syndrome following CURRENT-OASIS 7Johanne Silvain, Anne Bellemain-Appaix, Olivier Barthélémy, et al.
The American Journal of Cardiology|August 21, 2010
Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event ratesFarzin Beygui, Johanne Silvain, Ana Pena, et al.
Journal of the American College of Cardiology|August 31, 2010
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysisAnne Bellemain-Appaix, David Brieger, Farzin Beygui, et al.
Circulation. Cardiovascular Interventions|October 6, 2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patientsJean-Sébastien Hulot, Jean-Philippe Collet, Guillaume Cayla, et al.
Journal of the American College of Cardiology|July 13, 2010
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysisJean-Sébastien Hulot, Jean-Philippe Collet, Johanne Silvain, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 8, 2024
Impact of coronary sinus reducer on absolute coronary blood flow and microvascular resistanceClément Servoz, Stefan Verheye, Francesco Giannini, et al.
Case Reports in Cardiology|September 13, 2021
Anomalous Left Coronary Artery Connected to the Pulmonary Artery in a 15-Year-Old Girl: Case Report and Discussion on Secondary Prevention of Sudden DeathJérémy Laïk, Virginie Fouilloux, Philippe Aldebert, et al.
Pageof 5